Reilly Financial Advisors LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 0.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 96,116 shares of the company’s stock after selling 507 shares during the quarter. Johnson & Johnson comprises 1.9% of Reilly Financial Advisors LLC’s portfolio, making the stock its 11th largest position. Reilly Financial Advisors LLC’s holdings in Johnson & Johnson were worth $12,496,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Harding Loevner LP purchased a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. grew its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the last quarter. IHT Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc purchased a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $124,000. Institutional investors and hedge funds own 65.71% of the company’s stock.

Johnson & Johnson (NYSE JNJ) opened at $145.76 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $146.42. The firm has a market cap of $391,587.16, a P/E ratio of 25.31, a price-to-earnings-growth ratio of 2.75 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period last year, the firm earned $1.68 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. sell-side analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a yield of 2.31%. Johnson & Johnson’s payout ratio is presently 58.33%.

A number of research analysts recently weighed in on JNJ shares. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price objective on the stock. in a research report on Monday, September 18th. Goldman Sachs Group downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their price objective for the company from $125.00 to $130.00 in a research report on Wednesday, September 20th. Citigroup started coverage on shares of Johnson & Johnson in a research report on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective on the stock. Zacks Investment Research downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th. Finally, UBS Group restated a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a research report on Saturday, September 30th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $145.94.

ILLEGAL ACTIVITY NOTICE: “Reilly Financial Advisors LLC Sells 507 Shares of Johnson & Johnson (JNJ)” was reported by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2018/01/16/reilly-financial-advisors-llc-sells-507-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.